Related references
Note: Only part of the references are listed.Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions
Maarten A. Mensink et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis
Eric D. Shah et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
Lieke M. Spekhorst et al.
BMJ OPEN (2017)
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials
A. Cholapranee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
Andres J. Yarur et al.
GUT (2016)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
Stefanos Bonovas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis
Trine Olsen et al.
CYTOKINE (2016)
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action
Valentina Petito et al.
DIGESTIVE AND LIVER DISEASE (2016)
Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies
Vipul Yadav et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study
Jacoba M. Maurer et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis
Deborah S. Hartman et al.
JOURNAL OF CROHNS & COLITIS (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Alon D. Levin et al.
JOURNAL OF CROHNS & COLITIS (2016)
Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets
Vipul Yadav et al.
TRANSLATIONAL RESEARCH (2016)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Size and Molecular Flexibility of Sugars Determine the Storage Stability of Freeze-Dried Proteins
W. F. Tonnis et al.
MOLECULAR PHARMACEUTICS (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Immunopathogenesis of IBD: current state of the art
Heitor S. P. de Souza et al.
Nature Reviews Gastroenterology & Hepatology (2015)
Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans
Victoria S. Jasion et al.
NUTRITION JOURNAL (2015)
Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets
Jacoba M. Maurer et al.
PLOS ONE (2015)
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
R. W. Stidham et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Innate and adaptive immunity in inflammatory bowel disease
Alessandra Geremia et al.
AUTOIMMUNITY REVIEWS (2014)
In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects
Erik Sjogren et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sorcha O'Meara et al.
INFLAMMATORY BOWEL DISEASES (2014)
Intrinsic Tryptophan Fluorescence in the Detection and Analysis of Proteins: A Focus on Forster Resonance Energy Transfer Techniques
Amar B. T. Ghisaidoobe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort
Z. Vegh et al.
JOURNAL OF CROHNS & COLITIS (2014)
Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation
Jakob Hendel et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Local Injection of Infliximab in Symptomatic Isolated Mucosal Lesions: A Novel Scenario for Endoscopic Therapy?
V. Lorenzo-Zuniga et al.
INFLAMMATORY BOWEL DISEASES (2013)
Mechanisms of Action of Anti-tumor Necrosis Factor a Agents in Crohn's Disease
Simon T. C. Peake et al.
INFLAMMATORY BOWEL DISEASES (2013)
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability
J. M. Maurer et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Active and secreted IgA-coated bacterial fractions from the human gut reveal an under-represented microbiota core
Giuseppe D'Auria et al.
SCIENTIFIC REPORTS (2013)
A Non-Invasive, Low-Cost Study Design to Determine the Release Profile of Colon Drug Delivery Systems: A Feasibility Study
Marina J. M. Maurer et al.
PHARMACEUTICAL RESEARCH (2012)
Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery
Ana C. Freire et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study
L. Alessandroni et al.
TECHNIQUES IN COLOPROCTOLOGY (2011)
Oral ileocolonic drug delivery by the colopulse-system: A bioavailability study in healthy volunteers
R. C. A. Schellekens et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Proof-of-concept study on the suitability of C-13-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms
R. C. A. Schellekens et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
S. Danese
DIGESTIVE AND LIVER DISEASE (2008)
Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis
Arun Swaminath et al.
INFLAMMATORY BOWEL DISEASES (2008)
Gut instincts: Explorations in intestinal physiology and drug delivery
Emma L. McConnell et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab
C. Hassan et al.
DIGESTIVE AND LIVER DISEASE (2007)
A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products
R. C. A. Schellekens et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases:: A pilot study
Corrado R. Asteria et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Local injection of infliximab in the postoperative recurrence of Crohn's disease
L Biancone et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
M. M. Lawson et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Local injection of infliximab for the treatment of perianal Crohn's disease
G Poggioli et al.
DISEASES OF THE COLON & RECTUM (2005)
Inulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes
WLJ Hinrichs et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Immunoglobulin coating of faecal bacteria in inflammatory bowel disease
LA van der Waaij et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Investigations into the stabilisation of drugs by sugar glasses: I. Tablets prepared from stabilised alkaline phosphatase
HJC Eriksson et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs
SG Nugent et al.
GUT (2001)
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
F Cornillie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
